VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (US-OTC:
SRBCF) ("Sirona") is pleased to announce that it
has signed an agreement with Luxembourg-based analytics and marketing
specialist CURE Intelligence to manage online analytics and social
media communication.
The agreement was signed December
8th and will continue for a period of 12
months.
"We realize the power of social media in bringing awareness of
our technology to a greater audience both efficiently and with
improved content. We have been working to increase our virtual
presence and have now found a partner that can reach more potential
partners and expand our business development," said Dr.
Howard Verrico, CEO of Sirona
Biochem. "We look forward to this new relationship with the team at
CURE. During our due diligence, we've been impressed with their
commitment to hard work and their ability to add significant value
to our communications."
"Sirona Biochem is on the verge of a new chapter in the
company's history. After years of research and development of its
platform technology, the company is about to commercialize one of
its compounds and achieve other significant milestones. We look
forward to raising awareness of Sirona and its breakthrough
technology among targeted audiences through regular effective
content and data-driven distribution on social media," comments
Marco Feiten, Managing Director at
CURE Intelligence.
About CURE Intelligence
Founded in 2009, CURE specializes in the field of media
monitoring and analysis, data intelligence, social media
communications and content marketing. CURE helps its clients make
better decisions and improve internal and external communication
processes by effectively combining analytics and marketing.
CURE is a joint-stock company based in Grevenmacher,
Luxembourg, and works with
internationally renowned clients from Germany, Luxembourg, Canada and the U.S. For more information,
please visit www.cure-intelligence.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.